Formulary
Emtricitabine with tenofovir disoproxil: Indications, Dosing, Side Effects and Interactions
Emtricitabine with tenofovir disoproxil clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Emtricitabine with tenofovir disoproxil: Indications, Dosing, Side Effects and Interactions
Emtricitabine with tenofovir disoproxil clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**HIV-1 infection (initiated by a specialist)**
- **Adult** (By Mouth): 200/245 mg once daily.
**Pre-exposure prophylaxis of HIV-1 infection (initiated by a specialist)**
- **Adult** (By Mouth): 200/245 mg once daily.
**HIV-1 infection (initiated by a specialist) for emtricitabine with tenofovir disoproxil**
- **Child 12-17 years (body-weight 35 kg and above)** (By mouth): 200/245 mg once daily.
**Pre-exposure prophylaxis of HIV-1 infection (initiated by a specialist) for emtricitabine with tenofovir disoproxil**
- **Child 12-17 years (body-weight 35 kg and above)** (By mouth): 200/245 mg once daily.
Interactions
**Other interactions (43):**
- As Emtricitabine/ Tenofovir disoproxil contains emtricitabine and tenofovir disoproxil fumarate, any interactions that have been identified with these agents individually may occur with...
- The steady-state pharmacokinetics of emtricitabine and tenofovir were unaffected when emtricitabine and tenofovir disoproxil fumarate were administered together versus each medicinal product dosed...
- In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP450 mediated interactions involving emtricitabine and tenofovir disoproxil fumarate with other medicinal...
- Concomitant use not recommended Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil (as...
- Emtricitabine/ Tenofovir disoproxil should not be administered concomitantly with adefovir dipivoxil.
- Didanosine: The co-administration of Emtricitabine/ Tenofovir disoproxil and didanosine is not recommended (see section 4.4 and Table 2).
Hepatic impairment
For emtricitabine with tenofovir disoproxil Manufacturer advises caution (increased risk of hepatic side-effects).
Renal impairment
For emtricitabine with tenofovir disoproxil When used for HIV-1 infection: Manufacturer advises avoid in severe impairment. When used for Pre-exposure prophylaxis of HIV-1 infection: Manufacturer advises avoid if creatinine clearance less than 60 mL/minute. See Prescribing in renal impairment . Dose adjustments When used for HIV-1 infection: Manufacturer advises use normal dose every 2 days in moderate impairment.
Medicinal forms
Tablet
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Emtricitabine with tenofovir disoproxil in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

